Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01317017 · ClinicalTrials.gov registry record · Early Phase 1
Cell Responses to IFN-gamma
A Early Phase 1 study, sponsored by Rockefeller University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT01317017: Clinical Trial Early Phase 1 study, sponsored by Rockefeller University.
NCT01317017 is a Early Phase 1 study that was terminated before completion, run by Rockefeller University. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01317017, a Early Phase 1 study, was terminated before completion, sponsored by Rockefeller University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.
Primary Outcome
To perform an assay using dendritic cells from the biopsy as stimulator cells and T cells as responders.
Interventions
- DRUG Actimmune
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-05 |
| Phase | Early Phase 1 |
Why NCT01317017 stopped before completion
NCT01317017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Actimmune is the first listed.
NCT01317017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01317017 about?
NCT01317017 is a clinical study titled "Cell Responses to IFN-gamma". IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into th...
What is the current status of trial NCT01317017?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2010-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01317017?
The interventions under investigation include: Actimmune (DRUG).
Who is sponsoring clinical trial NCT01317017?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01317017's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia